Skip to main content

Free Content CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: a meta-analysis [Review article]

Download Article:
 Download
(PDF 426.556640625 kb)
 
BACKGROUND AND OBJECTIVE: A number of studies have evaluated the association between cytochrome P450 2E1 (CYP2E1) RsaI/PstI polymorphism and the risk of anti-tuberculosis drug-induced liver injury (ATDILI). However, the results were inconsistent. We conducted a meta-analysis to clarify the role of this polymorphism in ATDILI.

DESIGN: Two authors independently searched the PubMed, Medline, EMBASE and Chinese National Knowledge Infrastructure databases for studies on the association of CYP2E1 RsaI/PstI polymorphism with risk of ATDILI. Summary odds ratios (ORs) with their corresponding 95% confidence intervals (CIs) were calculated.

RESULTS: The combined results showed that the CYP2E1 c1/c1 genotype was associated with increased ATDILI risk compared to variant genotypes (c1/c2+c2/c2) (OR 1.36, 95%CI 1.09–1.69). When stratifying for study population, statistically significant results were observed in Chinese (OR 1.47, 95%CI 1.12–1.92) and Korean populations (OR 1.85, 95%CI 1.04–3.30). In comparison with CYP2E1 c1/c2 or c2/c2 with rapid/intermediate acetylators, the risk of ATDILI increased from 1.88 (95%CI 1.14–3.09) for CYP2E1 c1/c1 with rapid/intermediate acetylators to 6.44 (95%CI 3.47–11.97) for CYP2E1 c1/c1 with slow acetylators.

CONCLUSION: This meta-analysis suggests that CYP2E1 RsaI/PstI polymorphism may affect susceptibility to ATDILI, particularly among Chinese and Korean populations.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: CYP2E1 RsaI/PstI polymorphism; anti-tuberculosis drug-induced liver injury; meta-analysis

Document Type: Research Article

Affiliations: 1: Department of General Toxicology, National Shanghai Center for New Drug Safety Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, Shanghai, China; Department of General Toxicology, Shanghai InnoStar Bio-Tech Ltd, Shanghai, China 2: Department of Psychology, University of Southern California, Los Angeles, California, USA 3: Department of General Toxicology, National Shanghai Center for New Drug Safety Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, Shanghai, China 4: Department of General Toxicology, National Shanghai Center for New Drug Safety Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, Shanghai, China; Department of Pharmacology, School of Life Sciences, Northwestern Polytechnical University, Xi'an, Shaanxi Province, China

Publication date: 2012-12-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more